Opioid antagonists for pain

Bibliography

• Raffa RB, Pergolizzi JV Jr. Opioid formulations designed to resist/deter abuse. Drugs 2010;70(13):1657-75
   PubMed Web of Science ®Google Scholar
• Powell KJ, Abul-Husn NS, Jhamandas A, Paradoxical effects of the opioid antagonist naltrexone on morphine analgesia, tolerance, and reward in rats. J Pharmacol Exp Ther 2002;300(2):588-96
   PubMed Web of Science ®Google Scholar
• Leavitt SB. Opioid antagonists in pain management. Pract Pain Managment 2009;9(3):12-21
   Google Scholar
• Unterwald EM, Rubenfeld JM, Imai Y, Chronic opioid antagonist administration upregulates mu opioid receptor binding without altering mu opioid receptor mRNA levels. Mol Brain Res 1995;33(2):351-5
   PubMedGoogle Scholar
• Tempel A, Gardner EL, Zukin RS. Visualization of opiate receptor upregulation by light microscopy autoradiography. Proc Natl Acad Sci USA 1984;81(12):3893-7
   PubMed Web of Science ®Google Scholar
• Tempel A, Kessler JA, Zukin RS. Chronic naltrexone treatment increases expression of preproenkephalin and preprotachykinin mRNA in discrete brain regions. J Neurosci 1990;10(3):741-7
   PubMed Web of Science ®Google Scholar
• Romualdi P, Lesa G, Donatini A, Long-term exposure to opioid antagonists up-regulates prodynorphin gene expression in rat brain. Brain Res 1995;672(1-2):42-7
   PubMed Web of Science ®Google Scholar
• Wang HY, Friedman E, Olmstead MC, Ultra-low-dose naloxone suppresses opioid tolerance, dependence and associated changes in mu opioid receptor-G protein coupling and Gbetagamma signaling. Neuroscience 2005;135(1):247-61
   PubMed Web of Science ®Google Scholar
• Tsai RY, Tai YH, Tzeng JI, Ultra-low dose naloxone restores the antinociceptive effect of morphine in pertussis toxin-treated rats and prevents glutamate transporter downregulation by suppressing the p38 mitogen-activated protein kinase signaling pathway. Neuroscience 2009;159(4):1244-56
   PubMed Web of Science ®Google Scholar
• Tsai RY, Jang FL, Tai YH, Ultra-low-dose naloxone restores the antinociceptive effect of morphine and suppresses spinal neuroinflammation in PTX-treated rats. Neuropsychopharmacology 2008;33(11):2772-82
   PubMed Web of Science ®Google Scholar
• Tsai RY, Tai YH, Tzeng JI, Ultra-low dose naloxone restores the antinociceptive effect of morphine in pertussis toxin-treated rats by reversing the coupling of mu-opioid receptors from Gs-protein to coupling to Gi-protein. Neuroscience 2009;164(2):435-43
   PubMed Web of Science ®Google Scholar
• Wang HY, Frankfurt M, Burns LH. High-affinity naloxone binding to filamin a prevents mu opioid receptor-Gs coupling underlying opioid tolerance and dependence. PLoS One 2008;3(2):e1554
   PubMed Web of Science ®Google Scholar
• Wang HY, Burns LH. Naloxone's pentapeptide binding site on filamin A blocks Mu opioid receptor-Gs coupling and CREB activation of acute morphine. PLoS One 2009;4(1):e4282
   PubMed Web of Science ®Google Scholar
• Song P, Zhao ZQ. The involvement of glial cells in the development of morphine tolerance. Neurosci Res 2001;39(3):281-6
   PubMed Web of Science ®Google Scholar
• Narita M, Suzuki M, Yajima Y, Neuronal protein kinase C gamma-dependent proliferation and hypertrophy of spinal cord astrocytes following repeated in vivo administration of morphine. Eur J Neurosci 2004;19(2):479-84
   PubMed Web of Science ®Google Scholar
• Raghavendra V, Rutkowski MD, DeLeo JA. The role of spinal neuroimmune activation in morphine tolerance/hyperalgesia in neuropathic and sham-operated rats. J Neurosci 2002;22(22):9980-9
   PubMed Web of Science ®Google Scholar
• Tawfik VL, LaCroix-Fralish ML, Nutile-McMenemy N, Transcriptional and translational regulation of glial activation by morphine in a rodent model of neuropathic pain. J Pharmacol Exp Ther 2005;313(3):1239-47
   PubMed Web of Science ®Google Scholar
• Cui Y, Chen Y, Zhi JL, Activation of p38 mitogen-activated protein kinase in spinal microglia mediates morphine antinociceptive tolerance. Brain Res 2006;1069(1):235-43
   PubMed Web of Science ®Google Scholar
• Raghavendra V, Tanga F, DeLeo JA. Inhibition of microglial activation attenuates the development but not existing hypersensitivity in a rat model of neuropathy. J Pharmacol Exp Ther 2003;306(2):624-30
   PubMed Web of Science ®Google Scholar
• Sweitzer SM, Colburn RW, Rutkowski M, Acute peripheral inflammation induces moderate glial activation and spinal IL-1beta expression that correlates with pain behavior in the rat. Brain Res 1999;829(1-2):209-21
   PubMed Web of Science ®Google Scholar
• Kreutzberg GW. Microglia: a sensor for pathological events in the CNS. Trends Neurosci 1996;19(8):312-18
   PubMed Web of Science ®Google Scholar
• Watkins LR, Hutchinson MR, Rice KC, The "toll" of opioid-induced glial activation: improving the clinical efficacy of opioids by targeting glia. Trends Pharmacol Sci 2009;30(11):581-91
   PubMed Web of Science ®Google Scholar
• Hutchinson MR, Bland ST, Johnson KW, Opioid-induced glial activation: mechanisms of activation and implications for opioid analgesia, dependence, and reward. ScientificWorldJournal 2007;7:98-111
   PubMedGoogle Scholar
• Mattioli TA, Milne B, Cahill CM. Ultra-low dose naltrexone attenuates chronic morphine-induced gliosis in rats. Mol Pain 2010;6:22
   PubMed Web of Science ®Google Scholar
• Yang CP, Cherng CH, Wu CT, Intrathecal ultra-low dose naloxone enhances the antinociceptive effect of morphine by enhancing the reuptake of excitatory amino acids from the synaptic cleft in the spinal cord of partial sciatic nerve-transected rats. Anesth Analg 2011;113(6):1490-500
   PubMed Web of Science ®Google Scholar
• Tsai RY, Shen CH, Feng YP, Ultra-low-dose naloxone enhances the antinociceptive effect of morphine in PTX-treated rats: regulation on global histone methylation. Acta Anaesthesiol Taiwan 2012;50(3):106-11
   PubMedGoogle Scholar
• Capuano A, De Corato A, Treglia M, Peripheral antinociceptive effects of low doses of naloxone in an in vivo and in vitro model of trigeminal nociception. Neuropharmacology 2010;58(4-5):784-92
   PubMed Web of Science ®Google Scholar
• La Vincente SF, White JM, Somogyi AA, Enhanced buprenorphine analgesia with the addition of ultra-low-dose naloxone in healthy subjects. Clin Pharmacol Ther 2008;83(1):144-52
   PubMed Web of Science ®Google Scholar
• Movafegh A, Nouralishahi B, Sadeghi M, An ultra-low dose of naloxone added to lidocaine or lidocaine-fentanyl mixture prolongs axillary brachial plexus blockade. Anesth Analg 2009;109(5):1679-83
   PubMed Web of Science ®Google Scholar
• Movafegh A, Shoeibi G, Ansari M, Naloxone infusion and post-hysterectomy morphine consumption: a double-blind, placebo-controlled study. Acta Anaesthesiol Scand 2012;56(10):1241-9
   PubMed Web of Science ®Google Scholar
• Lunzer MM, Yekkirala A, Hebbel RP, Naloxone acts as a potent analgesic in transgenic mouse models of sickle cell anemia. Proc Natl Acad Sci USA 2007;104(14):6061-5
   PubMed Web of Science ®Google Scholar
• Tulunay FC, Takemori AE. The increased efficacy of narcotic antagonists induced by various narcotic analgesics. J Pharmacol Exp Ther 1974;190(3):395-400
   PubMed Web of Science ®Google Scholar
• Fabry ME, Nagel RL, Pachnis A, High expression of human beta S- and alpha-globins in transgenic mice: hemoglobin composition and hematological consequences. Proc Natl Acad Sci USA 1992;89(24):12150-4
   PubMed Web of Science ®Google Scholar
• Fabry ME, Sengupta A, Suzuka SM, A second generation transgenic mouse model expressing both hemoglobin S (HbS) and HbS-Antilles results in increased phenotypic severity. Blood 1995;86(6):2419-28
   PubMed Web of Science ®Google Scholar
• Solovey A, Kollander R, Shet A, Endothelial cell expression of tissue factor in sickle mice is augmented by hypoxia/reoxygenation and inhibited by lovastatin. Blood 2004;104(3):840-6
   PubMed Web of Science ®Google Scholar
• Rollins BJ. Chemokines. Blood 1997;90(3):909-28
   PubMed Web of Science ®Google Scholar
• Koch J, Manworren R, Clark L, Pilot study of continuous co-infusion of morphine and naloxone in children with sickle cell pain crisis. Am J Hematol 2008;83(9):728-31
   PubMed Web of Science ®Google Scholar
• Ling W, Hillhouse M, Jenkins J, Comparisons of analgesic potency and side effects of buprenorphine and buprenorphine with ultra-low-dose naloxone. J Addict Med 2012;6(2):118-23
   PubMed Web of Science ®Google Scholar
• Daitch J, Frey ME, Silver D, Conversion of chronic pain patients from full-opioid agonists to sublingual buprenorphine. Pain Physician 2012;15(3 Suppl):ES59-66
   PubMed Web of Science ®Google Scholar
• Rosenblum A, Cruciani RA, Strain EC, Sublingual buprenorphine/naloxone for chronic pain in at-risk patients: development and pilot test of a clinical protocol. J Opioid Manag 2012;8(6):369-82
   PubMedGoogle Scholar
• Hay JL, La Vincente SF, Somogyi AA, Potentiation of buprenorphine antinociception with ultra-low dose naltrexone in healthy subjects. Eur J Pain 2011;15(3):293-8
   PubMed Web of Science ®Google Scholar
• Dorn SD, Meek PD, Shah ND. Increasing frequency of opioid prescriptions for chronic abdominal pain in US outpatient clinics. Clin Gastroenterol Hepatol 2011;9(12):1078-85; e1
   PubMed Web of Science ®Google Scholar
• Smith JP, Stock H, Bingaman S, Low-dose naltrexone therapy improves active Crohn's disease. Am J Gastroenterol 2007;102(4):820-8
   PubMed Web of Science ®Google Scholar
• Smith JP, Bingaman SI, Ruggiero F, Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn's disease: a randomized placebo-controlled trial. Dig Dis Sci 2011;56(7):2088-97
   PubMed Web of Science ®Google Scholar
• Shannon A, Alkhouri N, Mayacy S, Low-dose naltrexone for treatment of duodenal Crohn's disease in a pediatric patient. Inflamm Bowel Dis 2010;16(9):1457
   PubMed Web of Science ®Google Scholar
• Kariv R, Tiomny E, Grenshpon R, Low-dose naltrexone for the treatment of irritable bowel syndrome: a pilot study. Dig Dis Sci 2006;51(12):2128-2133
   PubMed Web of Science ®Google Scholar
• Pain Therapeutics. Pain Therapeutics terminates drug candidate for the treatment of irritable bowel syndrome. 2005. Available from: http://investor. paintrials.com/releasedetail.cfm?ReleaseID=297360 [Cited 2012]
   Google Scholar
• Berger A, Sadosky A, Dukes EM, Patterns of healthcare utilization and cost in patients with newly diagnosed fibromyalgia. Am J Manag Care 2010;16(5 Suppl):S126-37
   PubMed Web of Science ®Google Scholar
• Younger J, Mackey S. Fibromyalgia symptoms are reduced by low-dose naltrexone: a pilot study. Pain Med 2009;10(4):663-72
   PubMed Web of Science ®Google Scholar
• Ramanathan S, Panksepp J, Johnson B. Is fibromyalgia an endocrine/endorphin deficit disorder? Is low dose naltrexone a new treatment option? Psychosomatics 2012;53(6):591-4
   PubMed Web of Science ®Google Scholar
• Attal N, Cruccu G, Baron R, EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol 2010;17(9):1113-e88
   PubMed Web of Science ®Google Scholar
• Hutchinson MR, Zhang Y, Brown K, Non-stereoselective reversal of neuropathic pain by naloxone and naltrexone: involvement of toll-like receptor 4 (TLR4). Eur J Neurosci 2008;28(1):20-9
   PubMed Web of Science ®Google Scholar
• Largent-Milnes TM, Guo W, Wang HY, Oxycodone plus ultra-low-dose naltrexone attenuates neuropathic pain and associated mu-opioid receptor-Gs coupling. J Pain 2008;9(8):700-13
   PubMed Web of Science ®Google Scholar
• Cruciani RA, Lussier D, Miller-Saultz D, Ultra-low dose oral naltrexone decreases side effects and potentiates the effect of methadone. J Pain Symptom Manage 2003;25(6):491-4
   PubMed Web of Science ®Google Scholar